OR WAIT null SECS
January 19, 2017
Astellas Pharma is the latest company to announce its participation in Access Accelerated, a global, multi-stakeholder initiative to advance access to non-communicable disease (NCD) prevention, diagnostics and treatment in low-income and lower-middle income countries.
Access Accelerated comprises 22 leading pharmaceutical companies, who, in collaboration with the World Bank Group and the Union for International Cancer Control (UICC), will work towards the United Nations Sustainable Development Goal target to reduce premature deaths from NCDs by one-third by 2030.
The contributing companies include Almirall, Astellas, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, EFPIA, GlaxoSmithKline, The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Johnson & Johnson, JPMA, Menarini, Merck, MSD, Novartis, Pfizer, PhRMA, Roche, Sanofi, Shionogi, Sumitomo Dainippon, Takeda and UCB.
IFPMA will act as the Secretariat for Access Accelerated.